A 64-year-old man with type 2 diabetes and hypertension has begun to experience generalized weakness. His laboratory results show a serum potassium level of 6.6 mEq/L (reference range, 3.5-5.0). How do you interpret the results?
This randomized clinical trial finds that sodium zirconium cyclosilicate reduced serum potassium levels among ambulatory patients with hyperkalemia.
This open-label randomized trial characterizes reductions in serum potassium levels and adverse events among patients with hyperkalemia and diabetes treated with patiromer, an oral potassium binder.